Haleon plc announced that Alan Stewart will succeed Vindi Banga as Senior Independent Director ("SID"), upon Vindi's appointment as Chair with effect from 1 January 2026. Alan Stewart joined the Board as a Non-Executive Director and Chair of the Audit & Risk Committee in September 2024. Alan will remain Chair of the Audit & Risk Committee and a member of the Remuneration Committee, Nominations & Governance Committee and Environmental & Social Sustainability Committee following his appointment as Senior Independent Director.
In accordance with the UK Corporate Governance Code 2024, Vindi will step down as a member of the Audit & Risk Committee effective 31 December 2025. Vindi will also step down as a member of the Remuneration Committee effective 31 December 2025 and be appointed Chair of the Nominations & Governance Committee effective 1 January 2026.
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows:
- oral health products (29.5%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.;
- Pain relief medicines (22.8%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.;
- medicines for digestive health (17.7%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.;
- vitamins, minerals and food supplements (15.1%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc.
- respiratory medicines (14.9%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.;
Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (41.2%), North America (36%), and Asia/Pacific (22.8%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
